

Data Sheet

Plasmid #33

SKU No.: 02-1033

Description	Plasmid #33 enables target proteins to be labeled with C-terminal His8 and CL7, retaining the His8 tag depending on the protease utilized.
Expression	Transcription is induced with IPTG and driven by the T7 RNA polymerase. The plasmid is designed for expression in E. Coli.
Affinity Tag	The C-terminal CL7 tag is downstream of three PreScission protease (PSC) cleavage sites, one Sortase A (SRT) cleavage site, and a His8 tag.
Cleavage Site(s)	Plasmid #33 includes an N-terminal SUMO cleavage site, three PSC, and one SRT C-terminal cleavage sites.
Other Tags	The encoded region begins with a Trx tag. A C-terminal His8 tag is also present upstream of the CL7 tag.
Resistance	Kanamycin
Form	100 ng, dissolved in H ₂ O.
Concentration	30 ng/μL
Stability	12 months after shipping
Storage	-20° C
Shipping	Room temperature

Scheme

1. HindIII/SpeI Insertion Site – Trx | SUMO | Gene of Interest | SRT | His8 | PSC | PSC | PSC | CL7

This insertion scheme results in 7 extra aa at the N terminus of the target following SUMO protease cleavage.

2. KpnI/SpeI Insertion Site – Trx | SUMO | Gene of Interest | SRT | His8 | PSC | PSC | PSC | CL7

This insertion scheme results in 2 extra aa at the N terminus of the target following SUMO protease cleavage.

3. Bsu36I/SpeI Insertion Site – Trx | SUMO | Gene of Interest | SRT | His8 | PSC | PSC | PSC | CL7

This insertion scheme maintains the Gene of Interest's wildtype sequence, without adding any extra residues. The N-terminus of the Gene of Interest must include the following to complete the SUMO C-terminal sequence:

P E D L D M E D N D I I E A H R E Q I G G
 CCTGAGGATCTGGACATGGAAGACAATGACATTATCGAAGCTCATCGTGAACAGATTGGTGGT<Gene of Interest>
 Bsu36I

You can download the full protocol from <https://trialtusbioscience.com/products/#protocols>.

**For research use only.
Not for diagnostic or therapeutic use.**

Licensing Information

TriAltus Bioscience holds the exclusive, worldwide license to the CL7 protein purification technology platform. It was licensed from the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, USA. An international patent filing has been made with protection being sought in the United States, Europe, and other major markets. The CL7 purification technology is available for research use. For commercial use or resale, contact us at sales@trialtusbioscience.com to discuss commercial licensing.

Trademarks

The Company name, the terms "TriAltus" and "TriAltus Bioscience", the Company logo, and all related names, logos, product and service names, designs, and slogans are trademarks of the Company or its affiliates or licensors. You must not use such marks without the prior written permission of the Company. All other names, logos, product and service names, designs, and slogans on this Website are the trademarks of their respective owners.

Version: 1.0
Revision Date: 11/20/2019